IFNL4 and hepatocellular carcinoma: Based on sequencing coverage rates, IFNL3 rs4803217 and IFNL3 rs28416813 were chosen as surrogates for the gain-or-loss dinucleotide polymorphism IFNL4 rs368234815 for HCC and PDAC patients, respectively.